Patent · US Active

Live genetically engineered protozoan vaccine

US7722860B2 · kind B2 · utility

2Cited by

3References

5Claims

0Family size

Assignee

Seattle Biomedical Research Institute · US

Inventors

Stefan H. I. Kappe · Seattle, US
Kai-Uwe C. Matuschewski · Berlin, DE
Ann-Kristin Mueller · Dossenheim, DE

Key dates

Filing date	Jun 22, 2005
Grant date	May 25, 2010
Priority date	—
Expiry date	Apr 9, 2028

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides methods for inducing an immune response in a vertebrate host against a protozoan parasite, comprising administering to the host a live protozoan parasite that is genetically engineered to disrupt a stage-specific gene function that is required by the protozoan parasite to establish a secondary infection in the vertebrate host. Representative protozoan parasites belong to the phyla Apicomplexa and Kinetoplastida. The vertebrate host may be a mammal or a bird.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.